Development

Editor of Pharmaceutical Technology Europe

Articles

Industry is adapting to the increasing complexity and poor solubility and bioavailability of molecules in the pipeline.

Adapting to Solubility/Bioavailability Challenges

Sergio A. Bernal-Chávez, PhD, is research associate at Laboratorio de Investigación y Posgrado en Tecnología Farmacéutica (L-322, Campo 1), Facultad de Estudios Superiores Cuautitlán, Universidad Nacional Autónoma de México.

Sergio Alcalá-Alcalá, PhD, is principal scientist at Laboratorio de Tecnología Farmacéutica, Facultad de Farmacia, Universidad Autónoma del Estado de Morelos, Cuernavaca, Morelos, México.

Doris Cerecedo, PhD, is principal scientist at Laboratorio de Hematobiología, Escuela Nacional de Medicina y Homeopatía, Sección de Estudios de Posgrado, Instituto Politécnico Nacional, Ciudad de México.

, is principal scientist at Laboratorio de Investigación y Posgrado en Tecnología Farmacéutica (L-322, Campo 1), Facultad de Estudios Superiores Cuautitlán, Universidad Nacional Autónoma de México.

The purpose of this article was to demonstrate the application of a new thermogelling matrix in the healing of wounds.

Thermogelling Matrix-Containing Platelet Lysate-Loaded Elastic Liposomes as a Potential Treatment of Wounds

Podcasts

In this episode, Fernando Muzzio provides greater insight into a novel approach to improving drug solubility—continuous melt coating.

Drug Solutions Podcast: Overcoming Poor Solubility Through Accelerated Dissolution

Biologics are forming a greater proportion of the development pipeline, but there are still some formulation difficulties to overcome to ensure clinical and commercial success.

Formulating Biologics: A Learning Curve 

Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.

Lack of toxicity data and poor physicochemical properties must be overcome.

Challenges to Formulation Development for Highly Potent APIs

Putting the patient at the forefront of drug development is essential, particularly to ensure medication compliance is optimized.

Focusing on the Patient in Drug Development

The right processes used with the right excipient combinations address evolving formulation needs.

Development of Coprocessed Excipients

Feliza Mirasol is the science editor for 

In this episode of the Drug Solutions Podcast, Feliza Mirasol, Pharmaceutical Technology’s science editor, discusses technologies enabling biologics and emerging therapies manufacturing and development with Barry Holtz, PhD, chief scientific officer of Phylloceuticals, and Professor Yaakov Nahmias, founder and chief scientific officer, Tissue Dynamics and founder and president, Future Meat Technologies.



Drug Solutions Podcast: Biologic Drug Development and Manufacturing

Grant Playter is the Assistant Editor for 

Recent trends in dissolution testing have led to increased use of data integrity solutions and more biorelevant testing techniques.

Advances in Dissolution Testing

Partnering with an experienced service provider can help companies unlock the commercial potential of new therapeutic approaches.